---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-049571"
form_type: "8-K"
ticker: "PVCT"
cik: "0000315545"
company_name: "PROVECTUS BIOPHARMACEUTICALS, INC."
filed_at: "2024-12-11T23:59:59+00:00"
generated_at: "2026-05-29T04:52:12.200433+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Provectus launches VisiRose subsidiary to develop RB PDAT for eye infections

## Summary
- VisiRose formed as Delaware subsidiary to commercialize rose bengal sodium for ophthalmology, targeting infectious keratitis.
- Seed round term sheet (non-binding) for up to $3M in three tranches at valuations tied to Series A; 5,278 Class B shares issued.
- University of Miami (Bascom Palmer) receives minority equity; 5% ownership until $2M qualified investment.
- Initial directors: Webster Bailey, Jack Lacey, Ed Pershing (Chair). Officers: Dominic Rodrigues (Acting CEO), Heather Raines (Acting CFO).
- RB PDAT tested in >500 patients globally; targeting $60B ophthalmic market with broad-spectrum antimicrobial therapy.

## SEC filing metadata
- accession: 0001493152-24-049571
- form_type: 8-K
- ticker: PVCT
- cik: 0000315545
- company_name: PROVECTUS BIOPHARMACEUTICALS, INC.
- filed_at: 2024-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/315545/000149315224049571/0001493152-24-049571-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/315545/000149315224049571/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-049571
- JSON: https://secwatch.observer/filing/0001493152-24-049571.json
- Plain text: https://secwatch.observer/filing/0001493152-24-049571.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.